|
Non-small cell lung cancer refractory to platinum-based therapy Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Non-small cell lung cancer refractory to platinum-based therapy conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Non-small cell lung cancer refractory to platinum-based therapy Clinical research trials and Non-small cell lung cancer refractory to platinum-based therapy medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Non-small cell lung cancer refractory to platinum-based therapy. Non-small cell lung cancer refractory to platinum-based therapy Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Non-small cell lung cancer refractory to platinum-based therapy clinical trial. Participants frequently get the best healthcare available for their Non-small cell lung cancer refractory to platinum-based therapy condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "N" Clinical Trials Conditions > Non-small cell lung cancer refractory to platinum-based therapy  Non-small cell lung cancer refractory to platinum-based therapy
Non-small cell lung cancer refractory to platinum-based therapy
For Condition: Carcinoma, Non-Small-Cell Lung
Status: Recruiting
Sponsor(s): Wyeth-Ayerst Research ,
Synopsis: This non-randomized, open-label clinical trial is designed to determine safety and clinical activity of a new chemotherapeutic agent, MAC-321, when given intravenously to patients with non-small cell lung cancer. Clinical activity will be evaluated by determining the percentage of patients with an objective tumor response after treatment with MAC-321. Patients must have been previously treated with a platinum-containing chemotherapy regimen. A total of 96 patients will be enrolled in this trial. Eligible patients will receive MAC-321 intravenously every 3 weeks for up to a total of 6 courses of treatment. All patients will receive MAC-321 at the same dose. MAC-321 is an experimental drug, and is not offered outside of this research trial.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: A physician participating in the study will determine eligibility, but if you meet the following criteria, you may qualify for this study: - Recurrence of non-small cell lung cancer after at least 1 prior chemotherapy regimen containing a platinum agent. - Recovery from all acute side effects of prior therapies (with the exception of hair loss). - Adequate bone marrow, liver, and kidney function Exclusion Criteria: - More than 2 prior chemotherapy regimens for treatment of advanced or metastatic non-small cell lung cancer. (Treatment given in conjunction with surgery will not be included in the maximum of 2 prior regimens). - Radiation therapy, chemotherapy or any other anticancer therapy within 28 days of beginning study. - Symptomatic brain metastases. - HIV, hepatitis B and/or hepatitis C infection. - Serious health problems such as uncontrolled serious infections, disabling heart disease, or uncontrolled major seizure disorder. - History of allergic reactions to docetaxel or paclitaxel. - Prior exposure to MAC-321.
Total Enrollment:
Location and Contact Information:
University of Sourthern California, Norris Comprehensive Cancer Center *Recruiting*
Los Angeles, California, 90033
United States
Recruiting Derek Raghavan 323-865-3962
University of Minnesota, Department of Medicine/HOT *Recruiting*
Minneapolis, Minnesota, 55455
United States
Recruiting Arkadiusz Dudek 612-624-6490
Markey Cancer Center *Recruiting*
Lexington, Kentucky, 40536-0098
United States
Recruiting Susanne Arnold 859-257-3379
Medical University of South Carolina *Recruiting*
Charleston, South Carolina, 29425
United States
Recruiting Carol Sherman 843-792-0670
Columbia University *Recruiting*
New York City, New York, 10032
United States
Recruiting Harry Raftopoulos 212-305-0787
John Hopkins Hospital Oncology Center *Recruiting*
Baltimore, Maryland, 21231-1000
United States
Recruiting Julie Brahmer 410-614-6139
Vanderbilt University *Recruiting*
Nashville, Tennessee, 37232
United States
Recruiting Alan Sandler 800-811-8480
University of Pittsburgh *Recruiting*
Pittsburgh, Pennsylvania, 15213
United States
Recruiting Chandra Belani 412-647-8569
Fox Chase/Temple Cancer Center *Recruiting*
Philadelphia, Pennsylvania, 19140
United States
Recruiting Joseph Treat 215-707-7410
Siteman Cancer Center *Recruiting*
St. Louis, Missouri, 63110
United States
Recruiting Ramaswamy Govindan 314-747-4235
University of Rochester Medical Center *Recruiting*
Rochester, New York, 14642
United States
Recruiting Kishan Pandya 585-275-8213
H. Lee Moffitt Cancer Center *Recruiting*
Tampa, Florida, 33612
United States
Recruiting Alberto Chiappori 813-972-8393
UMass Memorial Medical Center *Recruiting*
Worcester, Massachusetts, 01655
United States
Recruiting Jeff Gordon 508-334-6077
Carolinas Hematology-Oncology Associates *Recruiting*
Charlotte, North Carolina, 28203
United States
Recruiting Steven Limentani 704-355-8289
Cleveland Clinic *Recruiting*
Cleveland, Ohio, 44195
United States
Recruiting Tarek Mekhail 216-444-9451
Lombardi Cancer Center *Recruiting*
Washington D.C., District of Columbia, 20057
United States
Recruiting Jimmy Hwang 202-687-2561
Additional Information:
Study ID Numbers: 3128K1-201-WW;
Study Start Date:
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00063219
Other Carcinoma, Non-Small-Cell Lung Studies:
1. Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients with Stage III/IV and Relapsed NSCLC
2. A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin versus Gemcitabine and Cisplatin in Patients with Advanced, Previously Untreated Non-Small Cell Lung Cancer
3. Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer
4. Study of Cetuximab in Combination with Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer
5. ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have not had Previous Chemotherapy.
Related Studies:
Other Carcinoma, Non-Small-Cell Lung Clinical Trials
Other Tennessee Clinical Trials
Other Nashville Clinical Trials
Non-small cell lung cancer refractory to platinum-based therapy
|
|
|
|
|
|
|
|
